Reuters logo
BRIEF-Allergan gives 2018 guidance based on Restasis competition
November 1, 2017 / 12:46 PM / 22 days ago

BRIEF-Allergan gives 2018 guidance based on Restasis competition

Nov 1 (Reuters) - Allergan Plc

* Says expects 2018 non-GAAP EPS of no less than $15 if a Restasis generic competitor launches in january 2018

* Says expects 2018 non-GAAP EPS of no less than $16 if a Restasis generic competitor launches in july 2018

* Says expects 2018 non-GAAP EPS to be higher than 2017 if no Restasis generic competitor launches in 2018

* Says expects 2019 non-GAAP EPS to be higher than 2017 regardless of when a Restasis generic competitor launches Further company coverage: (Reporting By Michael Erman)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below